Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.
Mitzlaff K, Kirstein MM, Müller C, Venerito M, Olkus A, Dill MT, Weinmann A, Kocheise L, Busch A, Schulze K, Allo G, Waldschmidt DT, Barsch M, Bengsch B, Quante M, Gonzalez-Carmona MA, Himmelsbach V, Finkelmeier F, Kloeckner R, Schirmacher P, Marquardt JU, Zimpel C.
Mitzlaff K, et al. Among authors: muller c.
United European Gastroenterol J. 2024 Sep 20. doi: 10.1002/ueg2.12656. Online ahead of print.
United European Gastroenterol J. 2024.
PMID: 39301763